From project to portfolio, your team needs de-risking strategies, competitive assessments, and benchmarking to existing clinical drugs. At Eurofins Discovery, we understand the consequences for our clients of not devoting enough attention to these key issues.
Whether you have a first-in-class small molecule, biosimilar, antibody-drug conjugate (ADC) or even an artificial intelligence drug discovery program, many of our assay and services provide practical solutions for these diverse applications throughout the drug discovery cycle. Assays performed in human primary cells, complex co-cultures, and human cancer cell models are not enough these days to gain a competitive edge. Assays need validation with clinical candidates, advanced analytical approaches for maximum insights from biomarker readout results, and comprehensive reference databases for assignment of comparator and unique discriminator biomarker activities.
Our Asset Evaluation portfolio includes our industry-leading BioMAP® Platform for Profiling & Screening, with its comprehensive BioMAP Reference Database of 4,500+ approved drugs, failed drugs, antibodies, proteins, tool compounds, mixtures, and biomaterials.
Our OncoPanel® Platform provides 300+ immortalized human tumor cell lines, licensed from renowned repositories, for a breadth of in vitro models to use in cancer drug candidate evaluation. Clients use these proprietary platforms to evaluate combination strategies, repurpose existing drugs for new indications, and reposition a candidate early, if needed, for safety and toxicity data. Biomarker Services, Translational Cell Models, BioMAP, and OncoPanel teams are fluent in competitive benchmarking and due diligence. We take our QA/QC standards and regulations seriously, so you can have confidence in the quality of your data.
Approaches in Drug Repurposing and Repositioning
Figure. A variety of experimental and computational strategies may be involved in drug repurposing efforts. For these approaches to succeed, reference datasets must be accurate, complete, reliable and diverse. Eurofins Discovery BioPrint and BioMAP® Platforms rely on distinct but complementary assays to support repurposing strategies. With the exception of retrospective clinical data analysis, Eurofins Discovery provides services to address all approaches.
